Last reviewed · How we verify
Auriclosene Irrigation Solution, 0.2%
Auriclosene Irrigation Solution, 0.2% is a Antimicrobial Small molecule drug developed by NovaBay Pharmaceuticals, Inc.. It is currently in Phase 2 development for Treatment of mild to moderate diabetic foot ulcers.
Auriclosene Irrigation Solution is a topical antimicrobial agent that kills bacteria and fungi by disrupting their cell membranes.
Auriclosene Irrigation Solution is a topical antimicrobial agent that kills bacteria and fungi by disrupting their cell membranes. Used for Treatment of mild to moderate diabetic foot ulcers.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Auriclosene Irrigation Solution, 0.2% |
|---|---|
| Sponsor | NovaBay Pharmaceuticals, Inc. |
| Drug class | Antimicrobial |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 2 |
Mechanism of action
Auriclosene works by binding to the bacterial cell membrane, causing leakage of essential ions and ultimately leading to cell death. This mechanism of action is effective against a broad spectrum of microorganisms, including bacteria and fungi. The solution is designed for irrigation and cleansing of wounds and other infected areas.
Approved indications
- Treatment of mild to moderate diabetic foot ulcers
Common side effects
- Skin irritation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Auriclosene Irrigation Solution, 0.2% CI brief — competitive landscape report
- Auriclosene Irrigation Solution, 0.2% updates RSS · CI watch RSS
- NovaBay Pharmaceuticals, Inc. portfolio CI
Frequently asked questions about Auriclosene Irrigation Solution, 0.2%
What is Auriclosene Irrigation Solution, 0.2%?
How does Auriclosene Irrigation Solution, 0.2% work?
What is Auriclosene Irrigation Solution, 0.2% used for?
Who makes Auriclosene Irrigation Solution, 0.2%?
What drug class is Auriclosene Irrigation Solution, 0.2% in?
What development phase is Auriclosene Irrigation Solution, 0.2% in?
What are the side effects of Auriclosene Irrigation Solution, 0.2%?
Related
- Drug class: All Antimicrobial drugs
- Manufacturer: NovaBay Pharmaceuticals, Inc. — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Treatment of mild to moderate diabetic foot ulcers
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing